Claim check · Study interpretation
Tirzepatide and semaglutide in the same trial
Claim (representative wording, not a quotation): Tirzepatide and semaglutide have been compared head to head in a randomized trial.
Plain-English answer
Yes, in SURMOUNT-5, a 72-week open-label trial in adults with obesity: -20.2% with tirzepatide against -13.7% with semaglutide. Other weight-loss results for the two drugs come from separate trials and cannot be subtracted.
Verdict: Supported within scope. The sources WPF read support the claim as worded, for the stated population or organism, design, product and time. Nothing wider is implied.
What changed?
One change to this record since it was first published; this page shows version 1.6.0. Older versions still resolve.
· Source attribution corrected · Verdict unchanged
SURMOUNT-5 confidence intervals: arm intervals come from the abstract, the between-group interval from the registry
The correction changed source attribution only. Every estimate and every verdict stayed the same. The intervals were already correct; the records now say that the arm intervals come from the publication abstract and the between-group interval from the registry results, so a reader who goes to either source finds the figure where WPF says it is.
Read this change and its sources · Earlier record (version 1.4.0) · Updated record (version 1.5.0) · Correction Log entry
AI-assisted source verification. Documented human review: none recorded.
Scope
- Population or organism
- 751 adults with obesity, without type 2 diabetes
- Study design
- Randomized, open-label, phase 3b, 72 weeks, maximum tolerated doses
- Boundary
- This trial only. It says nothing about other doses, populations or outcomes.
Strongest evidence
SURMOUNT-5, result surmount-5-weight-72w (Flagship Weight Management 1.3.0) (WPF record)
Population or organism: 751 adults with obesity, without type 2 diabetes
Design: Randomized head-to-head, open-label
Where in the source: Point estimates: registry NCT05822830 results, primary outcome measure 1, posts -20.2 (tirzepatide) and -13.7 (semaglutide) as least-squares means, each with a standard error of 0.59, and a between-group least-squares mean difference of -6.5 (95% CI -8.1 to -4.9). The intervals -21.4 to -19.1 (tirzepatide's own mean) and -14.9 to -12.6 (semaglutide's own mean) and P<0.001 are from the NEJM abstract (PMID 40353578), not the registry; each belongs to one arm's mean, not to the difference between arms, and the abstract does not report the between-group difference.
ClinicalTrials.gov NCT05822830 (Registry record)
Population or organism: 751 randomized (375 tirzepatide, 376 semaglutide)
Design: Registered phase 3b trial, results posted 2025-11-26
Where in the source: Results tab, participant flow: 319 of 375 and 319 of 376 completed the study.
What remains uncertain
- The trial was open-label, so participants and investigators knew which drug they received.
- The publication abstract does not name the estimand. WPF matched the displayed values to the analysis plan by method.
- STEP 1 and SURMOUNT-1 are separate placebo-controlled trials; their percentages describe different populations and designs.
What would change the answer
- A second head-to-head trial with a different result, or a correction to the registry or publication.
Exact gaps
- The NEJM paper could not be opened by WPF's automated access (HTTP 403), so the table or figure that prints these numbers was not located.
Date checked and review status
Checked: · version 1.6.0
Review status: AI-assisted source verification. Human review: none recorded. Human review is pending and has not happened.
This check extends version 1.0.0, which stays available unchanged at its own address.
Related pages
Profiles: /directory/tirzepatide · /directory/semaglutide
Films: /films/metabolic/06-semaglutide
Flagship results: /research/flagship/compare/weight-management#surmount-5-weight-72w
Research journeys: /research/journey/semaglutide
Cite this check
The citation names the version and an address that keeps returning what was checked, even after a newer version is published.
Tirzepatide and semaglutide in the same trial: Yes, in SURMOUNT-5, a 72-week open-label trial in adults with obesity: -20.2% with tirzepatide against -13.7% with semaglutide. Other weight-loss results for the two drugs come from separate trials and cannot be subtracted. Verdict: Supported within scope. Cited from World Peptide Foundation, Peptide Claims & Evidence, version 1.6.0, claim tirzepatide-semaglutide-same-trial, checked 2026-11-16. AI-assisted source verification; human review none recorded.
Page:
https://www.worldpeptidefoundation.org/research/check/tirzepatide-semaglutide-same-trial
Versioned record:
https://www.worldpeptidefoundation.org/api/research/claims/tirzepatide-semaglutide-same-trial?version=1.6.0
Versioned record: /api/research/claims/tirzepatide-semaglutide-same-trial?version=1.6.0